实用医学杂志 ›› 2021, Vol. 37 ›› Issue (16): 2102-2108.doi: 10.3969/j.issn.1006⁃5725.2021.16.014

• 临床研究 • 上一篇    下一篇

HIV低病毒血症对艾滋病抗病毒治疗病毒学失败的影响

安靓1,2 ,劳云飞1, 唐松源2   

  1. 1 云南省传染病医院/云南省艾滋病关爱中心(昆明650301);2 昆明医科大学(昆明650500)


  • 出版日期:2021-08-25 发布日期:2021-08-25
  • 基金资助:
    云南省科技厅昆明医科大学应用基础研究联合专项资金项目(编号:202001AY070001⁃105)

Impact of HIV low ⁃level viraemia on virological failure among HIV/AIDS people receiving antiretroviral therapy

AN Jing*,LAO Yunfei,TANG Songyuan.   

  1. Yunnan Provincial Infectious Disease Hospital,Yunnan AIDS Care Center/ AIDS Clinical Management Office,Kunming 650301,China;*Kunming Medical University,Kunming 650500,China

  • Online:2021-08-25 Published:2021-08-25

摘要:

目的 研究艾滋病抗病毒治疗中 HIV 低病毒血症对后续病毒学失败的影响。方法 从中国艾滋病综合防治数据信息管理系统下载云南省艾滋病抗病毒治疗队列 2004 1 1 日至 2018 12 31 日随访数据进行回顾性观察研究。在一线治疗队列(不含克立芝)和二线治疗队列(含克立芝)中,将 数据分为低病毒血症组与无低病毒血症组,对不同水平和不同频率的患者之间的风险比(HR)采用多因 Cox 回归分析进行比较。结果 93 944 例病例纳入分析。一线治疗队列中,与无低病毒血症病例相比, 51 ~ 199 copies/mL组发生病毒学失败的风险没有变化,200 ~ 399 copies/mL组提高到1.39倍,400 ~ 999 copies/mL 组提高到 2.02 倍。单独一次(HR = 1.28,95%CI:1.21 ~ 1.36,P < 0.001)、连续两次(HR = 1.38,95%CI:1.22 ~ 1.55,P < 0.001)、连续多次(HR = 1.76,95%CI:1.48 ~ 2.10,P < 0.001)发生低病毒血症病例发生病毒学 失败的风险逐渐增加;在二线治疗队列中,与无低病毒血症病例相比,51 ~ 199 copies/mL 组发生病毒学失 败的风险没有变化,200 ~ 399 copies/mL 组提高到 1.33 倍,400 ~ 999 copies/mL 组提高到 2.26 倍。单独一次 HR = 1.27,95%CI:1.11 ~ 1.46)、连续两次(HR = 1.38,95%CI:1.02 ~ 1.88)发生低病毒血症的病例病毒学 失败的风险在增加。结论 200 ~ 999 copies/mL 或单独一次、连续发生的低病毒血症与后续病毒学失败相关,使之发生风险升高。

关键词:

艾滋病, 抗病毒治疗, 低病毒血症, 病毒学失败

Abstract:

Objective To learn about the impact of HIV low⁃level viraemia on subsequent virological failure in people living with HIV/AIDS undergoing antiretroviral therapy(ART). Methods A retrospective observational study was conducted based on the data of Yunnan′s cases extracted from National HIV/AIDS Comprehensive Information Management System from January 1,2004 to December 31,2018. Multivariate Cox regression was used to analyze the Hazard Ratio(HR)of virological failure in patients with different levels and frequencies of low⁃level viraemia compared with those without occurrence of low⁃level viraemia. They were divided into first⁃line ART cohort (regimen without LPV/r)and second ⁃line ART cohort(regimen with LPV/r ). Results A total of 93,944 cases were included in the analysis. In the first⁃line treatment cohort,compared with that without low⁃level viraemia,the risk rate of virological failure in the 51 ~ 199 copy /mL group was the same,but 1.39 times increased in the 200 ~ 399 copy /mL group,and 2.02 times in the 400 ~ 999 copy /mL group. Regarding to the frequencies of low viraemia occurrence,the risk of virological failure was gradually increased in cases suffering from low ⁃level viraemia once (HR = 1.28,95%CI:1.21 ~ 1.36,P < 0.001),twice consecutively(HR = 1.38,95%CI:1.22 ~ 1.55,P < 0.001 and several times consecutively(HR = 1.76,95%CI:1.48 ~ 2.10,P < 0.001). In the second⁃line treatment cohort the risk of virological failure was unchanged in the 51 ~ 199 copy/mL group,1.33 times increased in the 200 ~ 399 copy/mL group,and 2.26 times in the 400 ~ 999 copy/mL group,when compared with cases without low⁃level virae⁃ mia. There was an increased risk of virological failure in cases suffering from low⁃level viraemia once(HR = 1.27 95%CI:1.11 ~ 1.46)and twice consecutively(HR = 1.38,95%CI:1.01 ~ 1.88). Conclusion The ART cases suffering from viraemia with 200⁃999 copy /mL,or suffering from viraemia for once or or two or more times have the increased risk of subsequent virological failure. 

Key words:

HIV/AIDS, antiretroviral therapy, low?level viraemia, virological failure